PMID- 25603230
OWN - NLM
STAT- MEDLINE
DCOM- 20150828
LR  - 20181113
IS  - 1536-4798 (Electronic)
IS  - 0277-3740 (Print)
IS  - 0277-3740 (Linking)
VI  - 34
IP  - 3
DP  - 2015 Mar
TI  - Onset of ocular graft-versus-host disease symptoms after allogeneic hematopoietic 
      stem cell transplantation.
PG  - 243-7
LID - 10.1097/ICO.0000000000000340 [doi]
AB  - OBJECTIVE: To study the factors affecting the time to onset of ocular 
      graft-versus-host disease (GVHD) in patients undergoing allogeneic hematopoietic 
      stem cell transplantation (allo-HSCT). METHODS: A retrospective chart review of 
      200 patients with ocular GVHD was performed to evaluate the association between 
      various donor-recipient characteristics and the time to onset of ocular GVHD 
      after allo-HSCT. RESULTS: The median time to onset of chronic ocular GVHD after 
      allo-HSCT was 293 days (range, 26-2308 days). Patients receiving fully human 
      leukocyte antigen (HLA)-matched transplants had a delayed onset of ocular GVHD 
      (median, 294 days) compared with mismatched transplants (219 days; P = 0.029). 
      HLA-matched transplants from related donors had delayed onset of ocular GVHD (307 
      days) compared with HLA-matched (286 days; P = 0.168) and HLA-mismatched (231 
      days; P = 0.015) transplants from unrelated donors. Ocular GVHD followed systemic 
      GVHD in 76% of patients but preceded systemic disease in 7%, occurred 
      concurrently in 15%, and was not associated with systemic GVHD in 2% of patients. 
      The time elapsed between the occurrence of systemic and ocular GVHD was 
      significantly longer in matched-related transplants (250 days) than in 
      matched-unrelated transplants (120 days; P = 0.004). CONCLUSIONS: The onset of 
      ocular GVHD after allo-HSCT is variable and is influenced by donor-recipient 
      matching characteristics. In the majority of patients with GVHD, ocular 
      involvement follows the occurrence of systemic manifestations; however, 
      importantly, it can also precede or develop independently of systemic disease in 
      a minority of patients. Regular ophthalmic follow-up is recommended after 
      allo-HSCT regardless of concurrent systemic GVHD status.
FAU - Shikari, Hasanain
AU  - Shikari H
AD  - Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical 
      School, Boston, MA.
FAU - Amparo, Francisco
AU  - Amparo F
FAU - Saboo, Ujwala
AU  - Saboo U
FAU - Dana, Reza
AU  - Dana R
LA  - eng
GR  - K24 EY019098/EY/NEI NIH HHS/United States
GR  - EY19098/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Cornea
JT  - Cornea
JID - 8216186
SB  - IM
MH  - Adult
MH  - Aged
MH  - Conjunctival Diseases/epidemiology/*etiology
MH  - Corneal Diseases/epidemiology/*etiology
MH  - Female
MH  - Graft vs Host Disease/*epidemiology/etiology
MH  - Hematopoietic Stem Cell Transplantation/*adverse effects
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Massachusetts/epidemiology
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Tissue Donors
MH  - Transplantation Conditioning
MH  - Transplantation, Homologous
MH  - Young Adult
PMC - PMC4318713
MID - NIHMS642172
EDAT- 2015/01/21 06:00
MHDA- 2015/09/01 06:00
PMCR- 2016/03/01
CRDT- 2015/01/21 06:00
PHST- 2015/01/21 06:00 [entrez]
PHST- 2015/01/21 06:00 [pubmed]
PHST- 2015/09/01 06:00 [medline]
PHST- 2016/03/01 00:00 [pmc-release]
AID - 10.1097/ICO.0000000000000340 [doi]
PST - ppublish
SO  - Cornea. 2015 Mar;34(3):243-7. doi: 10.1097/ICO.0000000000000340.